| [1] |
Haugen BR, Alexander EK, Bible KC, et al.
2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. ThyroidThyroid, 2016, 26(1): 1-133.
doi: 10.1089/thy.2015.0020 |
| [2] |
丛慧, 梁军, 林岩松.
碘难治性分化型甲状腺癌的诊断与靶向治疗[J]. 国际放射医学核医学杂志国际放射医学核医学杂志, 2015, 39(1): 25-31.
doi: 10.3760/cma.j.issn.1673-4114.2015.01.007 Cong H, Liang J, Lin YS. Diagnosis and targeted therapy of radioactive iodine-refractory differentiated thyroid cancer[J]. Int J Radiat Med Nucl MedInt J Radiat Med Nucl Med, 2015, 39(1): 25-31. doi: 10.3760/cma.j.issn.1673-4114.2015.01.007 |
| [3] |
中华医学会核医学分会.
131I治疗分化型甲状腺癌指南(2014版)[J]. 中华核医学与分子影像杂志中华核医学与分子影像杂志, 2014, 34(4): 264-278.
doi: 10.3760/cma.j.issn.2095-2848.2014.04.002 Nuclear Medicine Society of Chinese Medical Association. Guidelines for the treatment of differentiated thyroid cancer with 131I (2014 ed)[J]. Chin J Nucl Med Mol ImagingChin J Nucl Med Mol Imaging, 2014, 34(4): 264-278. doi: 10.3760/cma.j.issn.2095-2848.2014.04.002 |
| [4] |
Licitra L, Locati LD.
Antiangiogenic TKIs and advanced RAI-resistant thyroid cancer: time for rethinking treatment strategies?[J]. ThyroidThyroid, 2014, 24(12): 1815-.
doi: 10.1089/thy.2014.0288 |
| [5] |
中国临床肿瘤学会(CSCO)甲状腺癌专家委员会, 中国研究型医院学会甲状腺疾病专业委员会, 中国医师协会外科医师分会甲状腺外科医师委员会, 等.
碘难治性分化型甲状腺癌的诊治管理共识(2019年版)[J]. 中国癌症杂志中国癌症杂志, 2019, 29(6): 476-480.
doi: 10.19401/j.cnki.1007-3639.2019.06.013 Thyroid Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO), Thyroid Disease Professional Committee of the Chinese Society of Research Hospitals, Thyroid Surgeon Committee of the Surgeon Branch of the Chinese Medical Doctor Association, et al. Consensus on the diagnosis, treatment and management of radioiodine-refractory differentiated thyroid cancer (2019 ed)[J]. China OncolChina Oncol, 2019, 29(6): 476-480. doi: 10.19401/j.cnki.1007-3639.2019.06.013 |
| [6] |
Schlumberger M, Brose M, Elisei R, et al.
Definition and management of radioactive iodine-refractory differentiated thyroid cancer[J]. Lancet Diabetes EndocrinolLancet Diabetes Endocrinol, 2014, 2(5): 356-358.
doi: 10.1016/S2213-8587(13)70215-8 |
| [7] |
Lakshmanan A, Wojcicka A, Kotlarek M, et al.
MicroRNA-339-5p modulates Na+/I− symporter-mediated radioiodide uptake[J]. Endocr Relat CancerEndocr Relat Cancer, 2015, 22(1): 11-21.
doi: 10.1530/ERC-14-0439 |
| [8] |
Brose MS, Nutting CM, Jarzab B, et al.
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial[J]. LancetLancet, 2014, 384(9940): 319-328.
doi: 10.1016/S0140-6736(14)60421-9 |
| [9] |
Schlumberger M, Tahara M, Wirth LJ, et al.
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J]. N Engl J MedN Engl J Med, 2015, 372(7): 621-630.
doi: 10.1056/NEJMoa1406470 |
| [10] |
中国临床肿瘤学会(CSCO)甲状腺癌专家委员会.
碘难治性分化型甲状腺癌靶向药物不良反应管理专家共识(2018年版)[J]. 中国癌症杂志中国癌症杂志, 2018, 28(7): 545-553.
doi: 10.19401/j.cnki.1007-3639.2018.07.012 Thyroid Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO). Expert consensus on the management of adverse reactions of targeted drugs in radioactive iodine-refractory differentiated thyroid cancer (2018 ed)[J]. China OncolChina Oncol, 2018, 28(7): 545-553. doi: 10.19401/j.cnki.1007-3639.2018.07.012 |